www.ema.europa.eu Availability of contentThe content from the previous version of this website is still available, including EMA’s bank of information on medicines.Former addresses (URLs) - such as links to pages and documents – also still work. These are either unchanged or, for the small...

www.ema.europa.eu The European Medicines Regulatory Network (EMRN) has been at the forefront of the fight against COVID-19 with its crucial role in the evaluation and monitoring of medicines, including vaccines. A joint report issued by the European Medicines Agency (EMA) and the Heads of...

www.ema.europa.eu PRAC recommends measures to minimise the risk of serious side effects with medicines containing pseudoephedrineEMA’s safety committee, PRAC, has recommended new measures for medicines containing pseudoephedrine to minimise the risks of posterior reversible encephalopathy...

www.ema.europa.eu European countries have substantially reduced sales of veterinary antibiotics, which translates into a lower risk of bacteria becoming resistant in people and animals. Overall sales of veterinary antibiotics decreased by 53% between 2011 and 2022, reaching the lowest level...

www.ema.europa.eu The Committee adopted by consensus positive opinions for variations requiring assessment concerning quality-related changes for:EquioxxOnsiorSimparica Trio, Felisecto Plus, MiPet Easecto, Simparica, Stronghold Plus (worksharing procedure) Vectormune ND, Newflend ND...

www.ema.europa.eu Eight new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended eight medicines for approval at its November 2023 meeting.The CHMP adopted a positive opinion for Omjjara* (momelotinib), for the treatment of myelofibrosis, a rare blood cancer...